Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

LNPs Europe
3-5 November 2026
Hotel Palace BerlinBerlin, Germany

Lorenz Mayr
Managing Director at BioMedTech Consulting GmbH
Speaker

Profile

Lorenz is working as Managing Director at BioMedTech Consulting GmbH in Basel, Switzerland. The company provides consulting service to BioPharma, Biotechnology and MedTech companies and academic institutions. He is also working as Chief Executive Officer (CEO) and Chairman of the Board (President) of PHiNE Bio AG, a new Biotech startup company in Basel, Switzerland which is operating since 08/2025 in stealth mode and financed by private investors. Lorenz has long-lasting experience in Pharma/Biotech investments and company creation from his work at Syncona Ltd (London, UK), Hevolution Foundation (Boston, MA) and EIT-Health Gold Track (Boston, MA; Munich, Germany). Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy. He has previously worked as a Chairman, Non-Executive Director, Chief Executive Officer, Chief Technology Officer, and Entrepreneur-in-Residence in the Biotech, Medtech, Pharma and Venture Capital industry across Europe and the US. He has received first class degrees in biochemistry, biophysics, molecular & cell biology at the University of Tubingen (Germany), University of Bayreuth (Germany) and the University of Colorado at Boulder (U.S.A.) and a number of fellowships & awards for his studies in Germany and the United States. Lorenz currently serves on the Board of Directors at Fundamental Pharma (Heidelberg, Germany), InCephalo (Basel, Switzerland) and PHiNE Bio AG (Basel, Switzerland), and serves on the Scientific Advisory Board of Fraunhofer IGB (Stuttgart, Germany), Fraunhofer IZI (Leipzig, Germany), SaxoCell (Leipzig), The Francis Crick Institute (London, UK), Science4Life (Stockholm, Sweden) SensibleBio (Oxford, UK), Hemotune (Zurich, Switzerland), Huidagene (Shanghai, China), AstraGenomics (Shanghai, China), TQ Therapeutics (Munich, Germany), GeneFab (San Francisco, CA) and NanoVation (Vancouver, Canada), and works as Senior Healthcare Advisor to EQT Investments (Stockholm/Sweden).

Agenda Sessions

  • Panel Discussion: Scale-Up Strategies: Navigating the Road Ahead for In Vivo CAR-T

    09:40